New analysis shows that more medicines worldwide are available to U.S. patients
By Kevin Haninger | June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...
Read More
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
By Randy Burkholder | June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative...
Read More
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
By Andrew Powaleny | May 30, 2018
In the not too distant past, chemotherapy and radiation were once the only treatments for what remains the second leading cause of death in the United States – cancer. Although the death rates of...
Read More
Spending on medicines grew less than one percent in 2017
By Holly Campbell | April 19, 2018
Last year, a record number of new treatments and cures that are transforming care for patients fighting debilitating diseases like cancer, hepatitis C, high cholesterol and more were approved by...
Read More
Patients pay the price when hospitals mark up cancer medicines
By Joe Vandigo | April 5, 2018
Two studies released last month reveal how hospitals across the country mark up the price of medicines and deliver a growing share of provider-administered medicines, resulting in higher costs...
Read More
A new era in cancer
By Andrew Powaleny | November 1, 2017
The last few years have seen unparalleled progress in cancer care, with breakthrough research driving major advances in diagnosis and treatment. Next week, on Wednesday, November 8, leading minds...
Read More
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
By Andrew Powaleny | October 12, 2017
The rapid pace of scientific advances has helped usher in a new era of medicine for cancer patients over the last decade. This morning, the National Institutes of Health (NIH) took a significant...
Read More
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
By Holly Campbell | September 12, 2017
This post has been updated as of 10/2/2017 A recent study published in JAMA Internal Medicine provides flawed and inaccurate estimates of the significant research and development (R&D) investments...
Read More
Protect your health: Important disaster preparedness tips for Harvey and Irma
By Guest Contributor | September 6, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
By Nicole Longo | June 12, 2017
We’ve seen significant progress in recent years in the treatment of cancer, and that progress is expected to continue. A new report released this month found that there are more than 240 new...
Read More
Medicare Monday (100)
340B Spotlight (35)
Cost & Consequence (0)
